These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9656099)

  • 41. [Natural follow-up of prostate cancer and consequences for early detection].
    Schmid HP
    Schweiz Rundsch Med Prax; 1993 Nov; 82(44):1239-43. PubMed ID: 7505945
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of patient age on the serum PSA concentration. An important clinical observation.
    Oesterling JE; Cooner WH; Jacobsen SJ; Guess HA; Lieber MM
    Urol Clin North Am; 1993 Nov; 20(4):671-80. PubMed ID: 7505975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of age-specific normal ranges for serum prostate-specific antigen.
    Slovacek KJ; Riggs MW; Spiekerman AM; Speights VO
    Arch Pathol Lab Med; 1998 Apr; 122(4):330-2. PubMed ID: 9648900
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between saliva PSA and serum PSA in conditions with prostate adenocarcinoma.
    Shiiki N; Tokuyama S; Sato C; Kondo Y; Saruta J; Mori Y; Shiiki K; Miyoshi Y; Tsukinoki K
    Biomarkers; 2011 Sep; 16(6):498-503. PubMed ID: 21854254
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The value of prostate-specific antigen in the management of localized prostatic cancer.
    Walsh PC; Oesterling JE; Epstein JI; Bruzek DJ; Rock RC; Chan DW
    Prog Clin Biol Res; 1989; 303():27-33. PubMed ID: 2476820
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Neuroendocrine differentiation and markers of cell proliferation in a group of patients with prostate adenocarcinoma and normal or high serum prostate-specific antigen levels].
    Feria-Bernal G; García-Gonzalez VM; Figueroa-Granados V; Martinez-Benítez B; Uribe-Uribe NO
    Gac Med Mex; 2006; 142(6):441-6. PubMed ID: 17201105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Enzyme-linked immunosorbent assay for serum prostate specific antigen (PSA) using monoclonal antibodies].
    Setoguchi C; Matsumoto K; Samori T; Kimura E; Harukaze S
    Rinsho Byori; 1998 Jan; 46(1):79-82. PubMed ID: 9492543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The role of PSA in prostatic adenocarcinoma].
    Manca GP
    Minerva Med; 1990 Apr; 81(4):261-4. PubMed ID: 1692981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate-specific antigen testing for prostate cancer. Practical interpretation of values.
    Randrup E; Baum N
    Postgrad Med; 1996 Feb; 99(2):227-8, 231-4. PubMed ID: 8632969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Percent free prostate-specific antigen: a marker for detection of prostate cancer].
    Miyanaga N; Uchida K; Akaza H
    Nihon Rinsho; 1998 Aug; 56(8):2006-11. PubMed ID: 9750497
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Prostate-specific antigen: the most useful marker for prostate cancer].
    Janssen T; Schulman C
    Rev Med Brux; 1993; 14(9-10):279-83. PubMed ID: 7508631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Non-palpable prostatic cancer. Cure with adenomectomy?].
    Cambronero Santos J; Carrero López V; Ortiz Vico FJ; Calahorra Fernández L; Rodríguez Antolín A; Passas Martínez J; Leiva Galvis O
    Actas Urol Esp; 1996 Apr; 20(4):346-50. PubMed ID: 8801795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostate-specific antigen (PSA) immunohistochemistry in the presence of a normal serum PSA as an aid to diagnosis of adenocarcinoma of unknown primary site.
    Harper CL; Lofts FJ; Otter M; Mansi JL
    Br J Hosp Med; 1996 Mar 20-Apr 2; 55(6):367-8. PubMed ID: 8696637
    [No Abstract]   [Full Text] [Related]  

  • 54. Is PSA necessary after prostatectomy?
    Kessenich CR
    Nurse Pract; 2010 Jan; 35(1):10-1. PubMed ID: 20027017
    [No Abstract]   [Full Text] [Related]  

  • 55. [The efficacy of PSA density for the early detection of prostate cancer].
    Kanehara H; Ueda H; Katsuoka Y
    Nihon Rinsho; 1998 Aug; 56(8):2012-5. PubMed ID: 9750498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Electrophoretic fingerprint metallothionein analysis as a potential prostate cancer biomarker.
    Krizkova S; Ryvolova M; Gumulec J; Masarik M; Adam V; Majzlik P; Hubalek J; Provaznik I; Kizek R
    Electrophoresis; 2011 Aug; 32(15):1952-61. PubMed ID: 21557258
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biomarkers for prostate cancer.
    Leman ES; Getzenberg RH
    J Cell Biochem; 2009 Sep; 108(1):3-9. PubMed ID: 19507229
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [PSA variations in persons with latent prostate cancer].
    Stamatiou K; Danciu M; Karakos C; Sofras F
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):126-9. PubMed ID: 18677916
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical usefulness of the new criteria based on the serum quantification of prostate-specific antigen in the early diagnosis of prostatic cancer].
    Morote Robles J
    Actas Urol Esp; 1996 Jan; 20(1):1-12. PubMed ID: 8720993
    [No Abstract]   [Full Text] [Related]  

  • 60. Serologic markers in prostate cancer.
    Harris D; Ruckle HC
    West J Med; 1996 Apr; 164(4):344-5. PubMed ID: 8732740
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.